{"@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{"@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.patentleaderboard.com/"}, {"@type": "ListItem", "position": 2, "name": "2021", "item": "https://www.patentleaderboard.com/2021/"}, {"@type": "ListItem", "position": 3, "name": "Schering", "item": "https://www.patentleaderboard.com/2021/company/schering"}, {"@type": "ListItem", "position": 4, "name": "Robert A. Kastelein", "item": "https://www.patentleaderboard.com/2021/inventor/fl:ro_ln:kastelein-2"}]}

Home › 2021 › Schering › Robert A. Kastelein

Robert A. Kastelein — 1 Patent in 2021

Merck: 1 patents #304 of 909Top 35%

Menlo Park, CA: #326 of 805 inventorsTop 45%

California: #26,007 of 66,859 inventorsTop 40%

Overall (2021): #284,275 of 548,734Top 55%

1 Patents 2021

Issued Patents 2021

Showing 1–1 of 1 patents

Patent #	Title	Co-Inventors	Date	Approx Value ⓘ
11052065	Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist	Elaine M. Pinheiro, Michael Rosenzweig, David KAUFMAN, Deborah Law	2021-07-06	$119,175,000

Robert A. Kastelein — 1 Patent in 2021

Issued Patents 2021

Patent Widget